Bausch + Lomb Corporation BLCO on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma ...

July 9 (Reuters) - Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of ...

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Bausch + Lomb will stop developing a topical eye drop for glaucoma after the drug failed to meet its primary endpoint in a phase 2 study. The company on Thursday said the drug, BL1107, didn't ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its ...

From memorable patient encounters to emerging therapies, OT talks with practitioners about opportunities and challenges in ...

The charity has encouraged optometrists to signpost eligible patients living with, or being monitored for, glaucoma to the ...

Glaucoma is a vision condition that results from damage to your optic nerve, often due to elevated pressure in the eye. It’s one of the most common causes of vision loss in adults and can lead to ...

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.